Pressure On Tecentriq: Bladder Cancer Heats Up With Opdivo Approval, Keytruda Filing
Executive Summary
Merck's filings in bladder cancer span first-line and second-line treatment and include overall survival data. Roche also is getting ready to move Tecentriq to the frontline setting.
You may also be interested in...
Keytruda/Chemo Combo Approval Means Merck Holds Crown, For Now
FDA's approval of Merck's Keytruda/chemo combo based on Phase II data secures the company's position in the prized first-line lung cancer indication, but Phase III readouts from other combination trials are right around the corner.
Bladder Cancer Market Wide Open As Tecentriq Fails Confirmatory 2L Trial
A cloud hangs over the approval of Roche's Tecentriq in the second line treatment of bladder cancer following the failure of a confirmatory Phase III trial. Meanwhile, rival product Bavencio from Merck KGaA and Pfizer has been granted accelerated approval by the FDA.
AstraZeneca's Imfinzi Debuts In Bladder Cancer With Combo Coming Soon
As many as five PD-1/L1 inhibitors will be approved for second-line metastatic disease by the end of 2017, but AstraZeneca hopes to stand apart with the combination of Imfinzi (durvalumab) with its CTLA-4 inhibitor tremelimumab.